BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20692189)

  • 1. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
    Hoefert S; Eufinger H
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):463-9. PubMed ID: 20692189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
    Bozas G; Roy A; Ramasamy V; Maraveyas A
    Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
    Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw related to sunitinib.
    Koch FP; Walter C; Hansen T; Jäger E; Wagner W
    Oral Maxillofac Surg; 2011 Mar; 15(1):63-6. PubMed ID: 20401503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan.
    Urade M; Tanaka N; Furusawa K; Shimada J; Shibata T; Kirita T; Yamamoto T; Ikebe T; Kitagawa Y; Fukuta J
    J Oral Maxillofac Surg; 2011 Nov; 69(11):e364-71. PubMed ID: 21782307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
    Carlson ER; Basile JD
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.
    Nicolatou-Galitis O; Migkou M; Psyrri A; Bamias A; Pectasides D; Economopoulos T; Raber-Durlacher JE; Dimitriadis G; Dimopoulos MA
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Feb; 113(2):234-8. PubMed ID: 22669112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
    Brunello A; Saia G; Bedogni A; Scaglione D; Basso U
    Bone; 2009 Jan; 44(1):173-5. PubMed ID: 18849018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib related osteonecrosis of jaw: a case report.
    Fleissig Y; Regev E; Lehman H
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Mar; 113(3):e1-3. PubMed ID: 22676833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?
    Otto S; Tröltzsch M; Jambrovic V; Panya S; Probst F; Ristow O; Ehrenfeld M; Pautke C
    J Craniomaxillofac Surg; 2015 Jul; 43(6):847-54. PubMed ID: 25958767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
    Thumbigere-Math V; Tu L; Huckabay S; Dudek AZ; Lunos S; Basi DL; Hughes PJ; Leach JW; Swenson KK; Gopalakrishnan R
    Am J Clin Oncol; 2012 Aug; 35(4):386-92. PubMed ID: 22561331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sunitinib and zoledronic acid induced osteonecrosis of the jaw].
    Soós B; Vajta L; Szalma J
    Orv Hetil; 2015 Nov; 156(46):1865-70. PubMed ID: 26548471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.
    Thumbigere-Math V; Sabino MC; Gopalakrishnan R; Huckabay S; Dudek AZ; Basu S; Hughes PJ; Michalowicz BS; Leach JW; Swenson KK; Swift JQ; Adkinson C; Basi DL
    J Oral Maxillofac Surg; 2009 Sep; 67(9):1904-13. PubMed ID: 19686928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
    O'Ryan FS; Lo JC
    J Oral Maxillofac Surg; 2012 Aug; 70(8):1844-53. PubMed ID: 22595135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
    Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
    J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital.
    Taylor T; Bryant C; Popat S
    Br Dent J; 2013 Apr; 214(7):E18. PubMed ID: 23579162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Encounter of cancer cells with bone. Present status and problems in occurrence of bisphosphonate-related osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2011 Mar; 21(3):420-7. PubMed ID: 21358064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.